Loading...
OTCM
PMDSF
Market cap107mUSD
, Last price  
USD
Name

Pharma Foods International Co Ltd

Chart & Performance

D1W1MN
OTCM:PMDSF chart
P/E
—
P/S
—
EPS
12.67
Div Yield, %
—
Shrs. gr., 5y
-0.22%
Rev. gr., 5y
33.56%
Revenues
65.26b
+5.01%
1,200,000,0001,107,000,000810,000,000734,000,000959,103,0001,006,661,0001,225,029,0001,524,506,0001,614,558,0002,165,708,0003,460,766,0004,722,596,0007,943,262,00010,532,834,00015,353,384,00046,752,000,00060,185,000,00068,572,000,00062,147,000,00065,260,000,000
Net income
368m
-88.52%
105,000,000-129,000,000-455,000,000-207,000,00015,246,000-46,602,00060,034,000269,346,0008,831,000-187,887,00025,896,000101,310,000313,662,000499,850,000690,947,0003,841,000,000-374,000,0003,080,000,0003,205,000,000368,000,000
CFO
-1.09b
L
343,000,000-289,000,000-139,662,000-129,344,000-32,823,000-18,782,000179,261,00016,763,000-218,500,000-242,112,000-35,298,000233,853,000415,543,00090,655,000-547,064,0005,938,000,000-6,065,000,0006,125,000,0005,486,000,000-1,092,000,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Pharma Foods International Co., Ltd. is a Japanese enterprise dedicated to the research, development, and commercialization of ingredients for functional foods. Its diverse product portfolio features items such as Pharma-GABA, Bonepep, Ovopron (a specific egg yolk globulin), Delicious Catechin, RunPep, and enriched Folic Acid Egg. Additionally, the company offers iHA, a compound recognized for stimulating the body's hyaluronic acid production. Furthermore, Pharma Foods International Co., Ltd. has entered into a licensing arrangement with Mitsubishi Tanabe Pharma Corporation for a novel therapeutic antibody designed to combat autoimmune conditions. The firm was founded in 1997 and maintains its corporate headquarters in Kyoto, Japan.
URL
https://www.pharmafoods.co.jp/
IPO date
Jun 12, 2006
Employees
624
Domiciled in
JP
Incorporated in
JP

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑072024‑072023‑072022‑072021‑072020‑072019‑072018‑072017‑072016‑07
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT